Clinical Trials for Ovarian Cancer

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic or unresectable solid tumors harboring AKT/PI3K/PTEN pathway alterations (excluding concurrent EGFR/KRAS/NRAS/HRAS/BRAF drivers) receive the investigational AKT-pathway inhibitor TER-2013 as monotherapy (expansion in ovarian/cervical/SCCHN/lung/esophageal and endometrial cancers) or with fulvestrant for HR+/HER2- breast cancer previously treated with an aromatase inhibitor. Prior AKT/PI3K/PTEN inhibitors (and prior SERD/mTOR in combo expansion) are excluded; requires ECOG 0–1 and adequate organ function.

ClinicalTrials.gov ID: NCT07109726

Phase 1a/1b Study of CT-95 in Advanced Cancers Associated With Mesothelin Expression

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with mesothelin-expressing advanced solid tumors (ECOG 0–1) receive weekly IV CT-95 (LNK-101), a mesothelin × CD3 T‑cell–engaging bispecific antibody engineered for reduced off‑tumor activation, in a dose-escalation/expansion study. Excludes prior mesothelin-targeted CD3/CAR‑T therapy; evaluates safety, PK, and preliminary efficacy across tumor types including mesothelioma.

ClinicalTrials.gov ID: NCT06756035

Phase I/II Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with TROP2-positive, platinum-resistant ovarian/peritoneal/fallopian tube cancer, mesonephric-like adenocarcinoma, or pancreatic/ampullary cancer with peritoneal/retroperitoneal disease receive lymphodepleting cyclophosphamide/fludarabine followed by a single intraperitoneal infusion of allogeneic cord blood–derived NK cells engineered with a TROP2-directed CAR and IL-15 for persistence. Designed to assess safety and preliminary efficacy of intraperitoneal TROP2 CAR-NK in heavily pretreated patients without active CNS disease or contraindications to IP therapy.

ClinicalTrials.gov ID: NCT05922930

A Phase 1, First in Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with CLDN6-positive advanced solid tumors—emphasizing platinum-resistant/refractory ovarian cancer (also endometrial or testicular)—with measurable disease and ECOG 0–2 receive weekly IV CTIM-76, a CLDN6×CD3 T cell–engaging bispecific antibody, in dose escalation and expansion cohorts. Excludes active/untreated CNS disease, prior CLDN6 therapy, uncontrolled infection; treatment continues until progression or toxicity.

ClinicalTrials.gov ID: NCT06515613

A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults (≥18; ≥15 for germ cell tumors) with CLDN6-positive advanced ovarian/fallopian tube/primary peritoneal cancer, endometrial adenocarcinoma, or germ cell tumors after standard therapy receive XmAb541, an investigational CLDN6×CD3 bispecific T‑cell–engaging antibody given IV or SC with step-up dosing. Excludes prior CLDN6-directed therapy, platinum-refractory ovarian cancer or rapid progression on ≥2nd-line, uncontrolled CNS metastases, active autoimmune disease, and significant comorbidities.

ClinicalTrials.gov ID: NCT06276491

Phase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic Cancers

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally recurrent ovarian, fallopian tube, primary peritoneal, endometrial, cervical, or vaginal cancers confined to the abdomen/pelvis receive daily oral talazoparib, a PARP1/2 inhibitor and potent PARP trapper/radiosensitizer, starting before and during fractionated external-beam radiation. Eligible patients must have ECOG 0–1 (or adequate life expectancy), adequate organ function, and at least one non-previously-irradiated measurable lesion; prior RT to the planned field, carcinomatosis/ascites/hepatic metastases, or need for extended-field RT are excluded.

ClinicalTrials.gov ID: NCT03968406

Phase II Clinical Trial of PLX038 in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Metastatic, platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer (initially platinum-sensitive; ≤1 prior line for platinum-resistant disease; prior PARP allowed) treated with PLX038, a long-acting pegylated prodrug of SN-38 (topoisomerase I inhibitor) given IV every 21 days until progression/toxicity. Excludes non–HGS histology and patients with UGT1A1 deficiency (e.g., Gilbert’s or homozygous UGT1A1*28).

ClinicalTrials.gov ID: NCT05465941

A Phase 1 Study to Evaluate TAG72-Targeting Chimeric Antigen Receptor (CAR) T Cells in Patients With Advanced Epithelial Ovarian Cancer

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent, platinum-resistant epithelial ovarian cancer whose tumors are TAG72-positive receive lymphodepleting fludarabine/cyclophosphamide followed by a single intraperitoneal infusion of autologous TAG72-directed CAR T cells. Investigational therapy targets the TAG72 glycoprotein to mediate CAR T–cell killing of peritoneal ovarian cancer; single-arm dose-escalation with long-term follow-up.

ClinicalTrials.gov ID: NCT05225363

Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Single-arm study for adults with recurrent primary mucinous ovarian cancer (ECOG 0–2) undergoing secondary cytoreductive surgery followed by intraoperative HIPEC using cisplatin. Aims to improve progression-free survival with a locoregional approach (heat-enhanced, DNA crosslinking cytotoxic agent) while evaluating perioperative toxicity and quality of life.

ClinicalTrials.gov ID: NCT05123807

Administration of T Cells Expressing B7-H3 Specific Chimeric Antigen Receptors (CAR) and Containing the Inducible Caspase 9 Safety Switch in Subjects With Recurrent Platinum Resistant Epithelial Ovarian Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent platinum-resistant or -refractory high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube carcinoma (ECOG 0–2) receive lymphodepleting cyclophosphamide/fludarabine followed by a single intraperitoneal infusion of autologous B7-H3 (CD276)–targeted CAR T cells incorporating an inducible caspase-9 safety switch (rimiducid-activatable). Single-arm dose-escalation with intraperitoneal port/catheter; serial biopsies required.

ClinicalTrials.gov ID: NCT06305299